Hepatitis B Surface Antigens

• 

  Subject Areas on Research

  • A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. 
  • A follow-up study of three hepatitis B virus markers in personnel from the Canadian Armed Forces. 
  • A program for eradication of hepatitis B from Taiwan by a 10-year, four-dose vaccination program. 
  • Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. 
  • Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. 
  • Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. 
  • Covalent complexes of antigen and alpha(2)-macroglobulin: evidence for dramatically-increased immunogenicity. 
  • Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. 
  • Different kinetics of HBV and HCV during haemodialysis and absence of seronegative viral hepatitis in patients with end-stage renal disease. 
  • Does hepatitis B surface antigen kinetics, including both decline and reaching a threshold, improve prediction of response? 
  • Downregulation of the AU-rich RNA-binding protein ZFP36 in chronic HBV patients: implications for anti-inflammatory therapy. 
  • Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials. 
  • Efficacy of hepatitis B screening in a private obstetrical population. 
  • Elimination of Perinatal Hepatitis B: Providing the First Vaccine Dose Within 24 Hours of Birth. 
  • Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. 
  • Genome-scale mutational signatures of aflatoxin in cells, mice, and human tumors. 
  • HBV-specific T-cell responses in healthy seronegative sexual partners of patients with chronic HBV infection. 
  • HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. 
  • HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration. 
  • Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. 
  • Hepatitis B core antibody-positive donors in cardiac transplantation: a single-center experience. 
  • Hepatitis B surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. 
  • Hepatitis B surface antigen could harbour the infective agent of AIDS. 
  • Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report. 
  • Hepatitis C infection in children with hemophilia A and B. 
  • Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination. 
  • Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge. 
  • Inducible expression of the alpha2-macroglobulin signaling receptor in response to antigenic stimulation: a study of second messenger generation. 
  • Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. 
  • Multiple types of immune complexes in patients with mixed cryoglobulinemia. 
  • Non-Hodgkin's lymphomas, version 1.2013. 
  • Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. 
  • Persistence of antibody in healthcare workers vaccinated against hepatitis B. 
  • Persistence of occult hepatitis B after removal of the hepatitis B virus-infected liver. 
  • Prevalence of hepatitis B among pregnant women and its impact on pregnancy and newborn complications at a tertiary hospital in the eastern part of Germany. 
  • Prevalence, aetiology and associated co-morbidities of elevated aminotransferases in a german cohort of orthopaedic surgery patients. 
  • Quantification of HBsAg and HBV-DNA during therapy with peginterferon alpha-2b plus lamivudine and peginterferon alpha-2b alone in a German chronic hepatitis B cohort. 
  • Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation. 
  • Relationship between transferrin saturation and iron stores in the African American and US Caucasian populations: analysis of data from the third National Health and Nutrition Examination Survey. 
  • Relevance of hepatitis B core gene deletions in patients after kidney transplantation. 
  • Response to hepatitis B immunization in children with hemophilia: relationship to infection with human immunodeficiency virus type 1. 
  • Review of the use of hepatitis B core antibody-positive kidney donors. 
  • Stable inhibition of hepatitis B virus proteins by small interfering RNA expressed from viral vectors. 
  • Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. 
  • The long-term course of hepatitis C after kidney transplantation. 
  • The relationship between hepatitis B surface antigen and antibody and continued drug use in narcotic dependency: a randomized controlled study. 
  • The risk of hepatitis B transmission from health care workers to patients in a hospital setting--a prospective study. 
  • Therapy of acute and fulminant hepatitis B. 
  • Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. 
  • Veterans health administration hepatitis B testing and treatment with anti-CD20 antibody administration. 
  • Virological and clinical characteristics of delta hepatitis in Central Europe. 
  • [Acute hepatitis B: is antiviral therapy indicated? Two case reports]. 
  • [Injuries from needles contaminated with hepatitis C virus: how high is the risk of seroconversion for medical personnel really?]. 
  • [Prevalence of hepatitis B in pregnancy and selective screening]. 
  • c-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma.